Performance Highlights - BeiGene (06160.HK) reported a revenue of 17.518 billion yuan for the first half of the year, a year-on-year increase of 46%; product revenue was 17.36 billion yuan, up 45.8%; net profit was 450 million yuan, turning from loss to profit [2] - Uni-President China (00220.HK) achieved approximately 17.087 billion yuan in revenue for the first half, a year-on-year increase of 10.6%; net profit was about 1.287 billion yuan, up 33.2% [2] - Zhiyu City Technology (09911.HK) announced a positive profit forecast, expecting mid-term revenue of approximately 3.135 to 3.215 billion yuan, a year-on-year increase of about 38.0% to 41.5%; net profit is expected to be around 470 to 510 million yuan, a year-on-year growth of approximately 108.9% to 126.7% [2] Earnings Forecasts - New World Development Company (00086.HK) expects mid-term net profit to increase to no less than 800 million HKD year-on-year [3] - Weizhi Jinkou (02003.HK) anticipates mid-term net profit exceeding 200 million HKD, a significant increase year-on-year [3] - Wing Chan Industrial (01596.HK) forecasts mid-term net profit of approximately 48.7 million HKD, turning from loss to profit [3] - Huaxian Optoelectronics (00334.HK) expects mid-term net profit to exceed 48.8 million HKD, a year-on-year increase of over 600% [3] - Maifushi (02556.HK) predicts mid-term net profit of approximately 31.8 to 41 million HKD, turning from loss to profit [4] - Xinwei Medical-B (06609.HK) expects mid-term net profit to exceed 40 million HKD, turning from loss to profit [5] - China Nuclear Technology (00611.HK) anticipates mid-term net profit growth of over 15% [6] Earnings Warnings - Hongxing Printing Group (00450.HK) expects mid-term net loss of approximately 49 million HKD, a significant increase year-on-year [7] - Zhongyu Land (01224.HK) forecasts mid-term net loss of approximately 40 million HKD, turning from profit to loss [7] - Beihai Group (00701.HK) anticipates mid-term net loss of 36 to 40 million HKD [8] Real Estate Sales Data - China Overseas Development (00688.HK) reported cumulative contract property sales of approximately 132 billion yuan for the first seven months, a year-on-year decrease of 18.3% [9] - Yuexiu Property (00123.HK) achieved cumulative contract sales of approximately 67.506 billion yuan for the first seven months, a year-on-year increase of about 11.7% [9] - Poly Property Group (00119.HK) reported contract sales of approximately 29.5 billion yuan for the first seven months, a year-on-year decrease of 13.49% [10] - China Overseas Hongyang Group (00081.HK) reported cumulative contract sales of 18.649 billion yuan for the first seven months, a year-on-year decrease of 12.2% [10] - Jindi Commercial Real Estate (00535.HK) reported cumulative contract sales of approximately 6.98 billion yuan for the first seven months, a year-on-year decrease of 37.37% [10] - Agile Group (03383.HK) reported pre-sale amount of approximately 5.69 billion yuan for the first seven months [11] - Hongyang Real Estate (01996.HK) reported cumulative contract sales of 3.208 billion yuan for the first seven months, a year-on-year decrease of 41.6% [12] - Zhengrong Real Estate (06158.HK) reported cumulative contract sales of approximately 2.701 billion yuan for the first seven months, a year-on-year decrease of 30.6% [12] - Jingrui Holdings (01862.HK) reported cumulative contract sales of approximately 571 million yuan for the first seven months, a year-on-year decrease of 52.54% [13] Company News - CITIC Securities (06030.HK) reported that its subsidiary, Huaxia Fund, achieved revenue of 4.258 billion yuan and net profit of 1.123 billion yuan in the first half, with assets under management totaling 285.1237 billion yuan [14] - Xinyi International (00732.HK) reported a cumulative operating revenue of approximately 9.566 billion HKD for the first seven months, a year-on-year decrease of about 5.3% [15] - Heng Rui Pharmaceutical (01276.HK) received orphan drug designation from the US FDA for its injection of Rikan Trastuzumab combined with Adebali for gastric cancer or gastroesophageal junction adenocarcinoma indications [15] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active renal glomerulonephritis in China [15] - China Biopharmaceutical (01177.HK) announced that its self-developed TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program for the treatment of chronic graft-versus-host disease [15] Buyback Activities - HSBC Holdings (00005.HK) repurchased approximately 1.65 billion HKD worth of about 1.714 million shares at a price of 95.8 to 96.75 HKD [16] - Hang Seng Bank (00011.HK) spent approximately 22.6347 million HKD to repurchase 200,000 shares at a price of 112.8 to 113.6 HKD [17] - Yum China (09987.HK) repurchased approximately 6.264 million HKD worth of 16,800 shares at a price of 369.8 to 376 HKD [17]

Core Viewpoint - China National Pharmaceutical Group's self-developed drug TQ05105 (Ruxolitinib) has been included in the Breakthrough Therapy Designation (BTD) program by the CDE for the treatment of chronic graft-versus-host disease (cGVHD) [1][2] Group 1: Drug Development and Approval - Ruxolitinib is the fastest progressing JAK/ROCK dual small molecule inhibitor globally [1] - The company submitted a marketing application for Ruxolitinib to the CDE in July 2024, which has been accepted for the treatment of intermediate to high-risk myelofibrosis (MF) [1] - Currently, Ruxolitinib is undergoing a Phase III clinical trial for cGVHD in China and has been approved for a Phase II clinical trial in the United States [1] Group 2: Clinical Trial Results - The Phase Ib/IIa clinical results for Ruxolitinib were published in the top journal "Blood," involving 44 patients with moderate to severe steroid-refractory or dependent cGVHD [2] - No dose-limiting toxicities were observed, and there were no adverse events leading to discontinuation related to Ruxolitinib [2] - The best overall response rate (BOR) was 86.4%, with a 12-month failure-free survival rate (FFS) of 85.2% [2] - 88.6% of participants reduced their steroid dosage requirements, and 59.1% experienced improvement in cGVHD-related symptoms [2] - The company is accelerating the global clinical development of Ruxolitinib to provide better treatment options for patients worldwide [2]

Core Insights - China National Pharmaceutical Group's self-developed drug TQ05105 (Ruxolitinib) has been included in the Breakthrough Therapy Designation (BTD) program by the CDE for the treatment of chronic graft-versus-host disease (cGVHD) [1][2] - Ruxolitinib is the fastest progressing JAK/ROCK dual small molecule inhibitor globally, with a marketing application submitted to CDE for myelofibrosis (MF) treatment [1] - The drug is currently undergoing Phase III clinical trials for cGVHD in China and has received approval for Phase II trials in the United States [1] Clinical Trial Results - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for malignant hematological diseases, with cGVHD being a major complication occurring in 30%-70% of cases [2] - Phase Ib/IIa clinical trial results published in the journal "Blood" included 44 patients with moderate to severe steroid-refractory or dependent cGVHD, showing no dose-limiting toxicities and no drug-related adverse events leading to discontinuation [2] - The best overall response rate (BOR) was 86.4%, with a 12-month failure-free survival rate (FFS) of 85.2%, and 88.6% of participants reduced their steroid dosage requirements, while 59.1% experienced improvement in cGVHD-related symptoms [2] - The company is accelerating the global clinical development of Ruxolitinib to provide better treatment options for patients worldwide [2]

Core Viewpoint - China Biologic Products (01177.HK) announced that its self-developed drug TQ05105 (a JAK/ROCK inhibitor) has been included in the Breakthrough Therapy Designation (BTD) program by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China for the treatment of chronic graft-versus-host disease (cGVHD) [1] Group 1 - TQ05105 is the fastest developing dual small molecule inhibitor of JAK/ROCK globally [1] - The company submitted a marketing application for TQ05105 to the CDE in July 2024, which has been accepted for the treatment of intermediate to high-risk myelofibrosis (MF) [1] - Currently, TQ05105 is undergoing a Phase III clinical trial for cGVHD in China, and has been approved to conduct a Phase II clinical trial in the United States [1] Group 2 - The Phase III clinical trial for TQ05105 in treating moderate to severe cGVHD is currently in the subject recruitment phase [1] - The company aims to accelerate the global clinical development of TQ05105 to provide better treatment options for patients worldwide as soon as possible [1]

（於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 羅伐昔替尼片「JAK/ROCK抑制劑」 納入突破性治療藥物程序 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的羅伐昔替尼片「TQ05105 （JAK/ROCK抑制劑）」已被中國國家藥品監督管理局藥品審評中心 (CDE)納入突破性治療藥物程序(BTD)，用於慢性移植物抗宿主病(cGVHD)的治療。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 異基因造血干細胞移植(allo-HSCT)是治療惡性血液系統疾病的一種有效方式，而慢性移植物抗宿主 病(cGVHD)是allo-HSCT的主要併發症之一，發生率可達30%-70%[1]。羅伐昔替尼的Ib/IIa期臨床結果 已發表於國際血液學領域頂級期刊《Blood》：該研究共納入44例中度或重度糖皮質激素難治性或依賴 性cGVHD患者， ...

截至2025年8月6日 10:32，中证香港创新药指数(931787)下跌1.33%。成分股方面涨跌互现，康希诺生物 (06185)领涨12.57%，晶泰控股(02228)上涨6.67%，远大医药(00512)上涨2.83%；君实生物(01877)领跌， 绿叶制药(02186)、三生制药(01530)跟跌。港股创新药ETF(513120)红盘蓄势。 流动性方面，港股创新药ETF盘中换手26.06%，成交43.40亿元，市场交投活跃。拉长时间看，截至8月 5日，港股创新药ETF近1周日均成交121.72亿元。 港股创新药ETF(513120)，（联接A:019670，联接C:019671）：紧密跟踪中证香港创新药指数，投资港 股创新药产业。值得注意的是，港股创新药ETF(513120)支持T+0交易，这意味着投资者可以在交易日 内进行多次买卖，极大地提高了资金的使用效率和流动性。 港股创新药ETF紧密跟踪中证香港创新药指数，根据申万二级行业分布，中证香港创新药指数生物制品 +化学制药权重占比达92.5%，这也是当下ETF跟踪的指数中，较为"纯血"的创新药行业指数之一。 数据显示，截至2025年7月31日，中证香 ...

Core Viewpoint - The Hong Kong stock market opened slightly lower on August 6, with innovative drugs continuing to be active, particularly the high-profile Hong Kong Stock Connect innovative drug ETF (520880), which rose by 1.37% in early trading, aiming for a third consecutive daily gain [1]. Group 1: Company Developments - On August 5, Crystal Tech Holdings announced a pipeline collaboration agreement with DoveTree, with a total order scale of approximately HKD 470 billion (USD 59.9 billion), marking one of the largest business development transactions in China's AI pharmaceutical sector by 2025 [2][3]. - Crystal Tech Holdings has received an initial payment of USD 51 million under the final agreement and is entitled to further payments of USD 49 million (to be paid within 180 days), as well as potential milestone payments of up to USD 5.89 billion based on regulatory and commercial achievements, along with royalties based on annual net sales [3]. Group 2: Industry Trends - The domestic innovative drug sector is entering a period of technological breakthroughs, with the National Medical Products Administration reporting that 43 innovative drugs were approved in the first half of the year, a year-on-year increase of 59%, nearing the total of 48 for the entire year of 2024 [3]. - According to China International Capital Corporation, the long-term development trend of the innovative drug industry is promising, supported by domestic engineer advantages, abundant clinical resources, and favorable policies [3]. - The innovative drug sector is expected to benefit from policy reforms in payment systems, enhancing the profitability of innovative drug companies, with many stocks in the sector showing strength as they enter the 2.0 era [3]. Group 3: Market Performance - The Hong Kong Stock Connect innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain, primarily consisting of innovative drug research and development companies [4]. - As of July 31, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has risen by 101.58% year-to-date, significantly outperforming the Hang Seng Index (23.50%) and the Hang Seng Tech Index (22.05%) by 78.08 and 79.53 percentage points, respectively [6][7].

Core Viewpoint - The Hong Kong stock market opened slightly lower on August 6, with innovative pharmaceuticals continuing to be active, particularly the high-profile Hong Kong Stock Connect innovative drug ETF (520880), which rose by 1.37% in early trading, aiming for a third consecutive daily gain [1]. Company Highlights - Crystal Tech Holdings (晶泰控股) announced a pipeline collaboration agreement with DoveTree, with a total order scale of approximately HKD 470 billion (USD 59.9 billion), marking one of the largest business development transactions in China's AI pharmaceutical sector by 2025 [2][3]. - Crystal Tech has received an initial payment of USD 51 million under the final agreement and is entitled to further payments of USD 49 million (to be paid within 180 days), as well as potential milestone payments of up to USD 5.89 billion based on regulatory and commercial achievements, along with royalties based on annual net sales [3]. Industry Trends - The National Medical Products Administration reported that 43 innovative drugs were approved in the first half of the year, a 59% year-on-year increase, nearing the total of 48 for the entire year of 2024 [3]. - According to China International Capital Corporation (中金公司), the long-term development trend of the innovative pharmaceutical industry is promising, supported by domestic engineering talent, abundant clinical resources, and favorable policies [3]. - The innovative drug sector is transitioning from a follower to a leader in innovation, with domestic products expected to significantly participate in the global market over the next decade [3]. Market Performance - The Hang Seng Stock Connect Innovative Drug ETF (520880) is the first ETF to passively track the Hang Seng Stock Connect Innovative Drug Select Index, focusing on the innovative drug industry chain with a high concentration of leading stocks [5]. - As of July 31, the Hang Seng Stock Connect Innovative Drug Select Index has risen by 101.58% year-to-date, outperforming the Hang Seng Index (23.50%) and the Hang Seng Technology Index (22.05%) by 78.08 and 79.53 percentage points, respectively [6].

Group 1 - The core viewpoint is that the Hong Kong innovative drug sector is experiencing significant growth, with the Hong Kong Innovative Drug Selected ETF seeing a rise of 1.2% and notable increases in individual stocks such as Jingtai Holdings and Lepu Biopharma [1] - The Hong Kong Innovative Drug Selected ETF (520690) has attracted substantial capital since its listing on August 1, with a net inflow of 29.54 million yuan over the past three trading days, bringing its total size to 359 million yuan [1] - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, focusing on leading innovative drug companies listed in Hong Kong, including companies like BeiGene, Innovent Biologics, WuXi Biologics, and others [1] Group 2 - The innovative drug sector is expected to remain a core focus within the pharmaceutical industry, with sustained optimism regarding its growth and internationalization [2] - The industry is anticipated to benefit from ongoing policy support, enhancing global competitiveness and commercial profitability [2] - The upcoming adjustments in medical insurance catalogs and the promotion of commercial insurance policies are seen as important catalysts for the innovative drug sector in the second half of the year [1]

Group 1 - The innovative drug sector is experiencing a strong surge, driven by the wave of BD (business development) going overseas, with the related ETF (589720) rising over 2% during trading [1] - The BD boom is a significant catalyst for the explosive growth of China's innovative drug market, with license-out transactions doubling year-on-year since 2025 [3] - Recently, major pharmaceutical companies have reached important licensing agreements, such as Heng Rui Pharma granting GSK exclusive global rights for PDE3/4 inhibitor HRS-9821, with an upfront payment of $500 million and potential milestone payments totaling around $12 billion [3] Group 2 - The application of AI in the pharmaceutical sector is igniting market sentiment, with expectations that AI will enhance the overall valuation of innovative drugs by improving R&D efficiency and reducing costs [4] - The innovative drug industry is poised for significant growth due to continuous breakthroughs in international markets, ongoing policy benefits, and the steady improvement of R&D capabilities among Chinese innovative drug companies [4] - Investors looking to capitalize on the high growth potential and internationalization opportunities in the innovative drug sector are encouraged to pay attention to the Guotai Innovative Drug ETF (589720) [4]